Cabozantinib shows promise in treating advanced adrenocortical cancer

According toA study published online in The Lancet Oncology on April 9, 2024, Cabozantinib shows promising efficacy in patients with advanced adrenocortical cancer. A single-arm phase II trial was conducted in adult patients with advanced adrenocortical cancer who were not candidates for surgical treatment, had an estimated life expectancy of at least 3 months, and had an Eastern Cooperative Oncology Group performance status of 0-2.

Patients took 60 mg of cabozantinib orally daily and had the option to reduce the dose to control adverse events. The median follow-up time was 36.8 months. The researchers found that 13 patients (72.2%) were progression-free at 4 months, with a median progression-free survival of 6 months. One patient is still receiving treatment. Eleven patients (61%) experienced grade 3 or worse treatment-related adverse events. The most common grade 3 adverse events were increased lipase, increased gamma-glutamyltransferase concentration, increased alanine aminotransferase concentration, hypophosphatemia, and hypertension (17, 11, 11, 11, and 11%, respectively). One patient developed grade 4 hypertension (6%). No treatment-related deaths were reported.

Cabozantinib shows promising activity and manageable safety in advanced adrenocortical cancer. The possible immunomodulatory effects of cabozantinib, if confirmed, may have the potential for combination immunotherapy treatment in patients with adrenocortical cancer.

The original drug Cabozantinib is not marketed in the country and therefore cannot be included in medical insurance. The original cabozantinib drug marketed overseas includes Japanese, European and Turkish versions. The price of tablets may be more than 30,000 yuan, and the price of capsule preparations may be more than 40,000 yuan (prices may fluctuate due to exchange rates).